ASX · AVR.AX
Anteris Technologies Ltd
A$8.83+A$0.28 (+3.27%)
Anteris Technologies Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.92% below the high.
Loading market information…
OTC · CMXC · USD
Stock price, earnings
Quote as of Nov 25, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cell MedX Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing, and marketing both therapeutic and non-therapeutic solutions aimed at individuals suffering from conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and various kidney-related ailments. The company's offerings include the eBalance Pro System, designed for clinical application by medical professionals, and the eBalance Home System, intended for personal use to promote general well-being and alleviate pain. Both systems are managed by the eBalance Console, a central control unit featuring three distinct pre-programmed microcurrent algorithms: wellness, pain management, and a dual mode. Originally established in 2010 as Sports Asylum, Inc., the company adopted its current name, Cell MedX Corp., in September 2014. Its operations are headquartered in Carson City, Nevada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$8.83+A$0.28 (+3.27%)
Anteris Technologies Ltd’s quoted price sits in the lower half of its reported 52-week range, 42.92% below the high.
$0.12$0.00 (0.0%)
Creso Pharma Limited: Healthcare · Drug Manufacturers - Specialty & Generic.
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
HK$0.90HK$0.00 (0.0%)
Tian An Medicare Limited’s quoted price sits in the lower half of its reported 52-week range, 34.19% below the high.
¥587¥0 (0.0%)
Japan Medical Dynamic Marketing, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.69% below the high.
$0.06$0.00 (0.0%)
Respiri Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$12.75-$13.25 (-50.96%)
Carmat S.A.: Healthcare · Medical - Devices.
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
